REGN
Regeneron Pharmaceuticals
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: REGN
- PE Ratio
As of Aug 21, 2026, the Regeneron Pharmaceuticals stock's PE ratio is 19.89. This takes into account the latest EPS of $41.94 and stock price of $834.04. The PE ratio marks an increase of 25% from its last 4 quarters average of 16.0.
REGN PE ratio history
The PE ratio of Regeneron Pharmaceuticals has averaged 21.33 over the last ten years. The current P/E ratio of 19.89 is 7% lower than the historical average. Looking back at the last ten years, REGN's PE ratio peaked in the Sep 2016 quarter at 52.62, when the price was $402.02 and the EPS was $7.64. The lowest point was in the Dec 2021 quarter, when it reached 8.27 with a price of $631.52 and an EPS of $76.4.
Regeneron Pharmaceuticals PE ratio by year
Maximum annual increase: 201.25% in 2013
Maximum annual decrease: -51.21% in 2016
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 17.92 | 2.87% | $771.87 | $43.07 |
| 2024 | 17.42 | -26.53% | $712.33 | $40.9 |
| 2023 | 23.71 | 33.13% | $878.29 | $37.05 |
| 2022 | 17.81 | 115.36% | $721.49 | $40.51 |
| 2021 | 8.27 | -44.12% | $631.52 | $76.4 |
| 2020 | 14.8 | -23.59% | $483.11 | $32.65 |
| 2019 | 19.37 | 17.47% | $375.48 | $19.38 |
| 2018 | 16.49 | -50.57% | $373.5 | $22.65 |
| 2017 | 33.36 | -22.29% | $375.96 | $11.27 |
| 2016 | 42.93 | -51.21% | $367.09 | $8.55 |
| 2015 | 87.99 | -27.94% | $542.87 | $6.17 |
| 2014 | 122.1 | 87.64% | $410.25 | $3.36 |
| 2013 | 65.07 | 201.25% | $275.24 | $4.23 |
| 2012 | 21.6 | N/A | $171.07 | $7.92 |
| 2011 | N/A | N/A | $55.43 | -$2.45 |
Regeneron Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Jun 2026 | 14.87 | -18.07% | $623.54 | $41.94 |
| Mar 2026 | 18.15 | 1.28% | $772.64 | $42.56 |
| Dec 2025 | 17.92 | 38.49% | $771.87 | $43.07 |
| Sep 2025 | 12.94 | 2.94% | $562.27 | $43.45 |
| Jun 2025 | 12.57 | -17.19% | $525 | $41.76 |
| Mar 2025 | 15.18 | -12.86% | $634.23 | $41.77 |
| Dec 2024 | 17.42 | -28.34% | $712.33 | $40.9 |
| Sep 2024 | 24.31 | -6.75% | $1,051.24 | $43.24 |
| Jun 2024 | 26.07 | -2.18% | $1,051.03 | $40.32 |
| Mar 2024 | 26.65 | 12.4% | $962.49 | $36.12 |
| Dec 2023 | 23.71 | 7.67% | $878.29 | $37.05 |
| Sep 2023 | 22.02 | 23.22% | $822.96 | $37.38 |
| Jun 2023 | 17.87 | -15.07% | $718.54 | $40.21 |
| Mar 2023 | 21.04 | 18.14% | $821.67 | $39.06 |
| Dec 2022 | 17.81 | 30.09% | $721.49 | $40.51 |
REGN Price vs fair value
REGN average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
REGN's current PE ratio is higher than the 3 and 5-year averages, but it is lower than its 10-year average.
PE comparison
With a price to earnings (P/E) of 19.89, REGN ranks higher than the industry average but lower than the Healthcare sector and its peers average. In comparison with the Healthcare sector average of 24.4, Regeneron Pharmaceuticals's price to earnings (P/E) is 18% lower.
REGN PE vs peers
Frequently asked questions
What is Regeneron Pharmaceuticals's PE ratio?
REGN stock has a price to earnings ratio of 19.89 as of Aug 21, 2026.
What is the 3-year average PE ratio for Regeneron Pharmaceuticals (REGN)?
The 3-year average price to earnings ratio for REGN stock is 19.32.
What is the 5-year average PE ratio for Regeneron Pharmaceuticals (REGN)?
The 5-year average price to earnings ratio for REGN stock is 17.0.
What is the highest PE ratio for REGN?
Over the last ten years, the quarterly PE ratio reached its highest level at 52.62 in the Sep 2016 quarter.
How does the current PE ratio for REGN compare to its historical average?
REGN's price to earnings ratio is currently 7% below its 10-year historical average.
How is REGN's PE ratio calculated (Regeneron Pharmaceuticals PE ratio formula)?
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Aug 21, 2026), Regeneron Pharmaceuticals's share price is $834.04. The company's earnings per share for the trailing twelve months (TTM) ending Jun 2026 is $41.94. Therefore, Regeneron Pharmaceuticals's PE ratio for today is 19.89. PE RATIO(19.89) = STOCK PRICE($834.04) / TTM EPS($41.94)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.